GOVX.OB

[setravis]

Here is a thread on DNTK are ready going.........

[Angelo921]

what???

[eric_lurie2002]

By my count these shares are gonna tank. HIV vaccine..no phase 1 trial to speak of...what's the good news...it's a an option on a dream...

[Angelo921]

they will not be tanking but rather be rebounding big time!!!

[eric_lurie2002]

too much dilution...run man...run.

[Angelo921]

im not worried. i even added more at .46

[gmarc66]

The news came in at there was a positive reactionn. How good is this news exactly in relation to the near future of this pps?

Tuesday, March 07 2006 12:18 PM, EST

Dauphin Technology Inc. Files an $18 Million Law Suit Against Stavros N. Papageorgiou, Nikolaos S. Papageorgiou, Miltos Louizidis, and Crescent International, Ltd.

SCHAUMBURG, Ill., March 7 /PRNewswire-FirstCall/ -- Dauphin Technology, Inc. ("Dauphin") (OTC: DNTK), a publicly traded company based in Schaumburg, Illinois, whose common stock trades on the Pink Sheets Electronic Quotation Service under the symbol DNTK.PK, today announced that it has filed legal action against preferred shareholders Stavros N. Papageorgiou and Nikolaos S. Papageorgiou, their advisor, Miltos Louizidis, and the investment banking firm of Crescent International, Ltd. (the "Defendants").

The complaint alleges, among other things, breaches of various agreements, fraud, tortious interference, conspiracy, and breaches of fiduciary duties by the Defendants. Specifically, Dauphin alleges that the Defendants embarked upon a scheme to defraud, tortiously interfere with contracts and business relationships, and to breach fiduciary duties in order to steal from Dauphin and its shareholders certain critical business opportunities, including its current efforts to merge with GeoVax, Inc.

The purpose of this action is to recover damages caused to the Company in prior business dealings and to protect the interests of current non-controlling (common) shareholders from the Defendants' recent attempts to sabotage the present merger plan with GeoVax, Inc., whereby, they would obtain significantly more shares for themselves at the cost of all common shareholders.

According to Andrew J. Kandalepas, Dauphin's CEO and Chairman, "the Defendants, have followed a consistent pattern of profiting schemes for the enrichment of themselves at the cost, work and achievements of others. This pattern is very apparent throughout the complaint whereby they have repeatedly caused harm to our Company and its shareholders by their unethical conduct, ever since the day I first introduced the Papageorgiou group to Crescent International, in mid 2004. Specifically, pertaining to the GeoVax merger, Dauphin's management has worked diligently towards the fulfillment of the transaction, where the Defendants continuously obstructed with our plans, for the sole purpose of satisfying their personal greed and to the detriment of the Dauphin project. With their relentless attempts to derail the project in order to steal it for themselves, they caused serious delays in our auditing efforts and subsequent closing of the merger itself. I strongly believe that the closing of the merger with GeoVax could have concluded much sooner, well within the year 2005, provided that the Defendants did not obstruct the process. Further, their motives and actions have seriously impacted our budget and overall costs of achieving our milestones to date."

"GeoVax's management has demonstrated its strong desire and willingness to complete its merger with Dauphin by its recent signing of the Merger Agreement," states GeoVax's CEO, Mr. Don Hildebrand. "The merger will conclude only as specified in the Merger Agreement and only with Dauphin's current management in place, which has worked tirelessly to increase shareholder value through this transaction," continues Mr. Hildebrand.

GeoVax, Inc. is a development stage biotechnology company established to develop, license and commercialize the manufacture and sale of human vaccines for diseases caused by the Human Immunodeficiency Virus (AIDS) and other infectious agents. Dauphin and GeoVax announced on January 24, 2006 their execution of a definitive Agreement and Plan of Merger (the "Merger Agreement").

"Concurring with Mr. Hildebrand, Dauphin, with its strong base of common shareholders behind it, remains poised and committed to conclude the GeoVax merger. GeoVax and its management have been very gracious to Dauphin throughout the process and do not deserve the kind of turbulence created by the Defendants. Similarly, Dauphin's shareholders do not deserve, should not be deprived, and should not allow another opportunity to be stripped away from them, as happened with the Arcadia affair earlier in 2004. However, I believe that filing this lawsuit is a positive step for the company towards completing the pending transaction with GeoVax, as it will deter the Defendants from interfering with the company's business opportunities, immediately," Mr. Kandalepas concluded.

Significant damages sought in the complaint are attributed to the Arcadia proposition, mentioned above, where the Defendants stripped the Company from an earlier opportunity to merge Dauphin with Arcadia Digital, S.A., a subsidiary of Sanyo Hellas Holdings, S.A., which is controlled by the Papageorgiou Defendants. Although this opportunity was introduced and orchestrated by Dauphin's CEO, the Papageorgiou Defendants, in collaboration with Crescent International, Ltd., secretly replaced Dauphin with another U.S. public vehicle to enhance their own financial gains.

The action filed by Dauphin does not prohibit any of the Company's shareholders, employees, affiliates, advisors, etc., from acting on their own behalf, independently, individually or jointly, in pursuing any potential action(s) against the Defendants.

No Stock Exchange has reviewed nor accepted responsibility for the adequacy or accuracy of the contents of this news release, which has been prepared by management. Statements contained in this news release that are not historical facts are forward-looking statements as that term is defined within the "safe harbor" provision as contained in the private securities litigation reform act of 1995. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from estimated results.

SOURCE Dauphin Technology Inc.

Contact Information: Dauphin Technology, Inc., +1-847-303-6566

[setravis]

Catch up on some of the Press Releases......


Press Release Source: GeoVax, Inc.; Dauphin Technology, Inc.


GeoVax, Inc. and Dauphin Technology, Inc. Announce Merger Agreement
Wednesday January 25, 8:00 am ET


ATLANTA and SCHAUMBURG, Ill., Jan. 25 /PRNewswire-FirstCall/ -- GeoVax, Inc. ("GeoVax"), a privately held biotechnology company based in Atlanta, Georgia, and Dauphin Technology, Inc. ("Dauphin"), a publicly traded company with no current business operations based in Schaumburg, Illinois whose common stock trades on the Pink Sheets Electronic Quotation Service under the symbol "DNTK.PK", today announced they have signed a definitive Agreement and Plan of Merger (the "Merger Agreement"). According to the Merger Agreement, Dauphin's wholly owned subsidiary, GeoVax Acquisition Corp., would merge with and into GeoVax, GeoVax would survive the merger as a wholly owned subsidiary of Dauphin and Dauphin would change its name to GeoVax Labs, Inc. (the "Merger"). In addition, GeoVax Labs, Inc. (formerly Dauphin) would obtain a new trading symbol as soon as the name change becomes effective.

    At the closing of the Merger (the "Closing"):

    --  The current shareholders of GeoVax and Dauphin would own approximately
        67% and 33%, respectively, of GeoVax Labs, Inc.'s outstanding capital
        stock, with the current shareholders of Dauphin holding the same
        number of shares they currently hold.

    --  GeoVax Labs, Inc. would issue an aggregate of approximately
        490.3 million shares of common stock to the shareholders of GeoVax in
        a non-registered transaction pursuant to Section 4(2) of the
        Securities Act of 1933, as amended (the "Securities Act"), or Rule 506
        promulgated thereunder.  Accordingly, such shares, and any additional
        shares issued in connection with the Merger, will be restricted
        securities as defined in Rule 144 promulgated under the Securities
        Act.

    --  GeoVax Labs, Inc. would have an aggregate of approximately
        733.3 million shares of common stock issued and outstanding, including
        shares to be issued to the GeoVax shareholders in connection with the
        Merger and to others in connection with any capital raising
        transactions occurring at or prior to the Closing.

    --  Emory University, which currently owns approximately 48% of the
        outstanding capital stock of GeoVax, would become the largest
        shareholder of GeoVax Labs, Inc., owning approximately 31% of GeoVax
        Labs, Inc.'s outstanding capital stock.

    --  GeoVax Labs, Inc. would have a total of seven directors, two
        designated by Dauphin's current management (one of whom is expected to
        be Andrew Kandalepas, Dauphin's current Chairman and Chief Executive
        Officer), and five designated by GeoVax.

    --  Donald Hildebrand would become the Chief Executive Officer of GeoVax
        Labs, Inc.

    --  Dauphin must have $13 million in cash that will remain as operating
        capital of GeoVax Labs, Inc. following the Closing.


The Merger is subject to customary closing conditions, including, among other things, approval by the shareholders of GeoVax and Dauphin, satisfactory completion of due diligence by both parties, confirmation of the parties' respective representations and warranties, elimination of substantially all of Dauphin's outstanding liabilities and compliance with all applicable legal requirements. In addition, prior to the Closing, Dauphin must become current in its reporting obligations under the Securities Exchange Act of 1934, as amended.

Regarding the Merger, GeoVax's Chief Executive Officer, Donald Hildebrand, stated, "I believe the proposed reverse merger with Dauphin offers us the quickest and most viable method to finance our anticipated Phase 1 and 2 clinical trials."

GeoVax believes the Merger will enable it to further develop, manufacture, test, conduct human trials, license and commercialize human vaccines for diseases caused by HIV-1 (human immunodeficiency virus) [AIDS] and other infectious agents. GeoVax has received private equity financing exceeding $5 million and its AIDS vaccine development programs have benefited from funding exceeding $21 million in competitive research grants provided by the U.S. National Institutes of Health (NIH) for AIDS vaccine development to Dr. Harriet L. Robinson, PhD, at the Emory University Vaccine Center. The AIDS vaccine technologies licensed by GeoVax from Emory University include technologies developed by the NIH and the U.S. Centers for Disease Control and Prevention (CDC).

GeoVax's Chief Executive Officer, Donald Hildebrand, a microbiologist with a 30-year career as a scientist and corporate leader in the biotechnology and vaccine industry, and GeoVax's Scientific Advisory Board Chair, Dr. Harriet L. Robinson, PhD, a microbiologist and immunologist at Emory University Vaccine Center, co-founded GeoVax in June 2001. GeoVax licensed its vaccine technology from Emory University, who developed the technology in collaboration with the NIH and CDC. GeoVax has rights to five issued patents, four recently approved patents and twelve filed patent applications.

GeoVax's Strong Pre-Clinical Data and Phase I Study

Regarding the GeoVax vaccine, Dr. Robinson stated, "The vaccine was developed over more than nine years and is based on the selection and evaluation of successive vaccine prototypes to provide protection against AIDS virus challenges in the monkey model. This selection process was our key to identifying a vaccine with high protective potential like the one we have advanced into human trials."

The GeoVax vaccine uses a two-part prime-boost approach designed to prime the body to recognize HIV and then boost T-cell and antibodies to fight the virus. This vaccine strategy consists of a DNA prime expressing multiple proteins from the HIV virus, followed by a booster vaccination using a recombinant poxvirus, again expressing multiple HIV proteins. The vaccine is designed to induce the human immune system, specifically T-cells and antibodies, to attack and destroy the actual AIDS (HIV-1) virus should it appear.

In 2004, the HIV Vaccine Trials Network (HVTN), a network sponsored by the NIH, completed a Phase 1 human study of GeoVax's DNA AIDS vaccine at three different sites in the U.S. with good safety results. HVTN plans to conduct Phase 1A and 1B human trials of GeoVax's DNA and MVA AIDS vaccines at multiple sites early in the second quarter of 2006, subject to FDA approval. These expanded trials should enable GeoVax to evaluate DNA combined with MVA and variations of its HIV/AIDS vaccine formulations and vaccination protocols for safety and their ability to stimulate immune responses.

Merger to Create Value for Current Dauphin Shareholders

Regarding the Merger, Andrew Kandalepas, Chairman and CEO of Dauphin, stated, "Closing the reverse merger with GeoVax would be a major milestone for our shareholders. Over the last two years, Dauphin has worked diligently to identify a merger candidate of GeoVax's stature, and we are pleased to have brought this strategy closer to fruition."

Concurrent with the publication of this press release, Dauphin has filed with the Securities and Exchange Commission a Current Report on Form 8-K describing the material terms of the Merger, including a copy of the Merger Agreement. The contents of this press release are qualified in their entirety by reference to the Form 8-K and the Merger Agreement.

Safe Harbor

This announcement contains express or implied forward-looking statements about Dauphin Technology, Inc.'s and GeoVax, Inc.'s (collectively, the "Company") future financial and operating results, products and business relationships. These statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those suggested in the forward-looking statements, including but not limited to, reliance on the manufacturing, sales and marketing efforts of a third party over which the Company has no direct control, enforceability, and validity of proprietary rights, ability to raise sufficient capital or borrow sufficient funds to fund future operations, ability to develop future products, technology shifts, potential technical or manufacturing difficulties that could delay products, competition, pricing pressures, the uncertainty of market acceptance of new products by customers, the outcome of any future litigation, ability to obtain and maintain regulatory approvals for products, general economic factors and other risks identified and discussed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements are based on information and management's expectations as of the date hereof. Future results may differ materially from the Company's current expectations. The Company disclaims any intent or obligation to update those forward-looking statements, except as required by law.




    BACKGROUNDER

                       GEOVAX'S PRIME-BOOST HIV VACCINE

GeoVax's prime-boost HIV vaccine incorporates a unique two-part approach that has shown exceptionally strong results in pre-clinical and early stage Phase I studies. The vaccine has been developed over the past nine years by one of the world's leading HIV/AIDS vaccine researchers, Dr. Harriet L. Robinson, PhD., chief of the Yerkes Division of Microbiology and Immunology and a faculty member of the Emory Vaccine Center of Emory University in Atlanta, with colleagues from the National Institutes of Health (NIH) and Centers for Disease Control and Prevention (CDC).


    A Two-Part Strategy
    --  The GeoVax prime-boost vaccine uses a unique two-part approach that
        primes the body to recognize HIV and then boosts T-cells and
        antibodies to fight the virus.
    --  This prime-boost strategy consists of priming with a DNA vaccine
        expressing the three major HIV-1 proteins followed by boosting with a
        recombinant poxvirus expressing the same proteins.
    --  The vaccine induces the immune system to respond to a broad spectrum
        of targets within HIV-1 so the system will be able to control the
        virus and prevent escape should an infection occur.


    Clinical Studies

    Pre-clinical
    --  A pre-clinical study of the GeoVax prime-boost vaccine involving 23
        primates was published in the journal Science in 2001.
    --  Results from this study showed 96% protection over a 3-1/2 year period
        of time.
    --  In these trials, viral levels were controlled to the nearly
        undetectable levels characteristic of a small subset of HIV-infected
        people, termed long-term non-progressors, who are infected with HIV
        but do not develop AIDS.
    --  In contrast, five out of six unvaccinated monkeys died within 8
        months.


    Phase I
    --  Beginning in 2003, Phase I safety trials of the DNA component were
        conducted by the U.S. HIV Vaccine Trials Network (HVTN), an
        NIH-sponsored international collaboration of scientists and educators.
    --  A total of 30 human volunteers were enrolled at the University of
        Alabama at Birmingham, the University of Washington in Seattle and the
        San Francisco Department of Public Health.
    --  The study was completed in 2004 and showed excellent safety.


    Ongoing
    --  Phase Ia/Ib clinical studies will begin in 2006, conducted by the
        HVTN.
    --  These trials will evaluate safety of the prime combined with the
        boost, and provide more in-depth information about the human immune
        response.


    Safety
    --  The GeoVax vaccine produces the three major proteins expressed by HIV
        to induce the immune system to identify a broad spectrum of HIV-1
        targets.  It does not produce HIV-1 and poses no risk for infection.
    --  Our vaccine is delivered using intramuscular injections.
        -   The first component of the vaccine, the DNA prime, is purified DNA
            that codes for HIV genes.  Vaccines using purified DNA have been
            safely used in over 1000 humans.
        -   The second component, the MVA boost, is an attenuated version of
            the vaccine used for smallpox.  The parent version of this MVA has
            been safely administered to over 120,000 humans.


    About HIV/AIDS
    --  AIDS is considered the most lethal pandemic infectious disease in the
        world, with an estimated 16,000 new infections daily.
    --  In the U.S., over 1 million people are infected.  It is estimated that
        sub-Sahara African populations are up to 30 percent infected with AIDS
        virus with South Africa at or about 35 percent.
    --  Globally, over 40 million people are infected, 6 million people are
        infected yearly, 22 million people have died of AIDS, 3 million people
        are dying annually, and 68 million people are projected to die by
        2020.


    For More Information, Contact:

    Investor Relations:
    Andrew Kandalepas
    Chairman and Chief Executive Officer
    Dauphin Technology
    847-303-6566

    Media:
    Joseph Poulos
    Edelman
    312-240-2719
--------------------------------------------------------------------------------
Source: GeoVax, Inc.; Dauphin Technology, Inc.

[setravis]

Press Release Source: Dauphin Technology, Inc.


Dauphin Technology Inc. (DNTK) SqueezeTrigger Price is $0.50; Approximately 9.9 million Shares Shorted Since January 2005 According To Buyins.net Research Report
Tuesday February 7, 9:00 am ET


SCHAUMBURG, Ill., Feb. 7 /PRNewswire-FirstCall/ -- DauphinTechnology, Inc., today announced that it has engaged BUYINS.NET http://www.buyins.net to initiate coverage and provide SqueezeTrigger Reports on the company's stock (OTC: DNTK - News) short selling data. The first report releases the latest short sale data from January 2005 to February 2006. For this period, approximately 128.4 million total aggregate shares of DNTK have traded for a total dollar value of nearly $64.2 million. The total aggregate number of shares shorted in this time period is approximately 9.9 million shares. The DNTK SqueezeTrigger price of $0.50 is the volume weighted average short price that all shorts are short shares of DNTK. A short squeeze will begin when shares of DNTK exceed $0.50. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://buyins.net/squeezetrigger.pdf .


    Month          Total Volume  Short Volume  Avg. Price  Short Dollar Value

    January '05     5,068,956      390,310       $0.168        $65,377
    February       12,125,387      933,655       $0.216       $201,950
    March           5,328,260      410,276       $0.251       $103,061
    April           8,302,807      639,316       $0.284       $181,438
    May             4,677,494      360,167       $0.303       $108,951
    June           11,444,990      881,264       $0.393       $345,896
    July            7,038,415      541,958       $0.455       $246,591
    August          3,672,668      282,795       $0.450       $127,258
    September       3,832,334      295,090       $0.443       $130,577
    October        19,560,478    1,506,157       $0.616       $928,094
    November        7,489,076      576,659       $0.670       $386,361
    December       10,014,508      771,117       $0.798       $614,966
    January '06    27,016,960    2,080,306       $0.672     $1,396,925
    February        2,803,238      215,849       $0.505       $109,004

    Total:        128,375,571    9,884,919       $0.500     $4,946,449

    *short volume is approximated using a proprietary algorithm.
    **average short price is calculated using a volume weighted average short
     price.
    ***short volume is the total short trade volume and does not account for
     covers.


                    DNTK On OTC Naked Short Threshold List

    On List            Off List              # Days

    January 7, 2005    January 13, 2005      5
    February 4, 2005   February 23, 2005     13

Dauphin Technology Inc. has been on the OTC Naked Short Threshold list 2 times. Brokerage firms have been out of compliance with Regulation SHO once, and are currently violating Regulation SHO by not forcing naked shorts to cover. Regulation SHO took effect January 3, 2005, and provides a new regulatory framework governing short selling of securities. It was designed with the objective of simplifying and modernizing short sale regulation and providing controls where they are most needed. At the conclusion of each settlement day, data is provided on securities in which: 1) there are at least 10,000 shares in aggregate failed deliveries for the security for five consecutive settlement days, and 2) these failures constitute at least 0.5% of the issuer's total shares outstanding. SEC Regulation SHO, under the Securities Exchange Act of 1934, mandates that, if a clearing agent has had a fail-to-deliver position for 13 consecutive settlement days, that clearing agent, and the broker/dealer it clears for, must purchase securities to close out its fail to deliver position.

About Dauphin Technology Inc.

Dauphin Technology, Inc. ("Dauphin"), is a publicly traded company with no current business operations based in Schaumburg, Illinois whose common stock trades on the Pink Sheets Electronic Quotation Service under the symbol "DNTK.PK". Dauphin announced on January 25, 2006 the signing of a definitive Agreement and Plan of Merger (the "Merger Agreement"). According to the Merger Agreement, Dauphin's wholly owned subsidiary, GeoVax Acquisition Corp., would merge with and into GeoVax, GeoVax would survive the merger as a wholly owned subsidiary of Dauphin and Dauphin would change its name to GeoVax Labs, Inc. (the "Merger"). In addition, GeoVax Labs, Inc. (formerly Dauphin) would obtain a new trading symbol as soon as the name change becomes effective.

About BUYINS.NET

WWW.BUYINS.NET is a service designed to help bonafide shareholders of publicly traded US companies fight naked short selling. Naked short selling is the illegal act of short selling a stock when no affirmative determination has been made to locate shares of the stock to hypothecate in connection with the short sale. Buyins.net has built a proprietary database that uses Threshold list feeds from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the naked short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted and naked shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short and naked short trades.

BUYINS.NET has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 600,000,000 short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like Buyins.net to access the data.

The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each month's short transactions, BUYINS.NET provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.

All material herein was prepared by BUYINS.NET, based upon information believed to be reliable. The information contained herein is not guaranteed by BUYINS.NET to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. Dauphin Technology Inc. has paid a $995.00 data fee for information provided in this report. The data service can be cancelled at any time. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. BUYINS.NET is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. BUYINS.NET will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected", "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10- KSB and other filings made by such company with the SEC.
--------------------------------------------------------------------------------
Source: Dauphin Technology, Inc.

[setravis]

Press Release Source: ExchangeBlvd.com, Inc.


ExchangeBlvd.com Establishes AIDSReliefAuction.org to Fund Disease Research and Relief Efforts
Tuesday February 7, 11:42 am ET 
Charity Auction Features Celebrity Items and Memorabilia


ATLANTA--(BUSINESS WIRE)--Feb. 7, 2006--ExchangeBlvd.com (OTC: EXBV.PK - News), a leading provider of online auction services, expands its marketplace with AIDSReliefAuction.org, a charity initiative to support AIDS related causes. AIDSReliefAuction.org will feature an impressive array of donated celebrity collectibles, fan experience events and entertainment merchandise. Since its inception in 1999, ExchangeBlvd.com's charity auctions have raised over $1 Million for non-profit and healthcare institutions.

ExchangeBlvd.com will develop AIDSReliefAuction.org through a series of corporate and non-profit partnerships. GeoVax Inc., a developmental stage biotechnology company specializing in AIDS and other human vaccines, which recently announced a merger agreement with Dauphin Technology, Inc (OTC: DNTK.PK - News), is the first corporation to commit to the project.

AIDSReliefAuction.org goes live in April, 2006. Unlike similar initiatives, 100% of the proceeds will go to AIDS related programs; ExchangeBlvd.com will assume the administrative costs typically deducted from public gifts. ExchangeBlvd.com will manage the sale with its propriety auction marketplace technology, procure merchandise, and grow the number of participating organizations. The company will also link AIDSReliefAuction.org to its subsidiaries, GolfClubExchange.com and InstrumentExchange.com.

"We're excited to use our online auction expertise for such a worthy cause. There has been tremendous interest in AIDSReliefAuction.org and we couldn't be happier with the response from celebrities, corporations and prospective bidders," comments Larry Tedesco, CEO and President of ExchangeBlvd.com. "With over 40 million people afflicted with AIDS worldwide, this auction is an opportunity for the public to help tackle the epidemic."

As part of ExchangeBlvd.com's efforts, the first moneys raised will help fund GeoVax Inc.'s AIDS vaccine clinical trials in places such as India and Sub-Saharan Africa, where the disease has reached pandemic levels.

"ExchangeBlvd.com's commitment to raising awareness through AIDSReliefAuction.org and their history of successful online charity programs makes it an ideal partner," stated Don Hildebrandt, CEO of GeoVax, Inc. "This initiative will hopefully help bring GeoVax AIDS Vaccine clinical trials to global markets, and further the development and evaluation of a vaccine designed to safely prevent the clinical signs of AIDS."

To learn more about AIDSReliefAuction.org, please contact Andy Schechter at 678-775-1733.

About ExchangeBlvd.com, Inc.

ExchangeBlvd.com, Inc., based in Duluth, GA owns and operates industry specific online auction marketplaces and other Internet based properties including GolfClubExchange.com, InstrumentExchange.com, and GolfClubDemo.com. The company provides consumers, manufacturers, and retailers a groundbreaking solution for liquidating specialty products by integrating proprietary auction marketplace technology with traditional brick and mortar merchandising. Additionally, ExchangeBlvd.com enables retailers to sell inventory through multiple marketplaces simultaneously while managing the entire sales process from one location. For more information visit www.ExchangeBlvd.com.

Contact:
Lippert/Heilshorn & Associates
Gretchen Steinmiller/Chenoa Taitt, 212-838-3777
[email protected]

--------------------------------------------------------------------------------
Source: ExchangeBlvd.com, Inc.

[setravis]

GEOVAX Merger
GEOVAX @$5.00 is valued at 3.7 Billion Dollars. That's correct. 3.7 Billion.
This is a very very good move for DNTK shareholders.
PnF's on the weekly charts are Bullish.

Upside targets are .76... 2.06 and 3.20

Candlestick Analysis 
Today's Candlestick Patterns:
Doji
Today a Doji was formed. This shows indecision about the direction of the market and it represents a tug-of-war between buyers and sellers.

[setravis]

Let's see how it goes this week.

Technicals
Last Price Quote is:
3.80%above 13-day EMA
23.16%above 50-day EMA
RS Rating: N/A 

Fundamentals
Key Data:
Market Cap (M): $64.71 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: N/A
Last Analyst Rating: N/A

[setravis]

Geovax Labs, Inc. (GOVX.OB)


Profile for: 

Geovax Labs, Inc.
1256 Briarcliff Road NE
Emtech Bio
Atlanta, GA 30306
United States - Map
Phone: 404-727-0971
Fax: 404-712-9357
Web Site: http://www.geovax.com

BUSINESS SUMMARY   
GeoVax Labs, Inc., a biotechnology company, engages in the development and testing of human vaccines for diseases caused by human immunodeficiency virus-AIDS and other infectious agents. The company completed a phase I human trial of prototype DNA. GeoVax Labs, Inc. was founded in 2001 and is based in Atlanta, Georgia.

[setravis]

Making a move off a Double Bottom (reversal) Pattern.
Let's see if it has anything to offer.

[setravis]

It just may have it going on now...